Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

BALY Cover Image

Check out the companies making headlines this week:

Bally's (NYSE:BALY): Gaming, betting and entertainment company Bally's Corporation (NYSE:BALY) rose by 11.6% on Thursday after the stock continued to rally as reports revealed that the company is weighing a sale of development rights for its roughly $1.1 billion mixed-use project around the Athletics’ future Las Vegas ballpark. See our full article here.

Is now the time to buy Bally's? Access our full analysis report here, it’s free.

Adobe (NASDAQ:ADBE): Creative software giant Adobe (NASDAQ:ADBE) rose by 4.5% on Tuesday after asset-management giant BlackRock increased its stake to more than 10% of the company See our full article here.

Is now the time to buy Adobe? Access our full analysis report here, it’s free.

Novavax (NASDAQ:NVAX): Vaccine biotechnology company Novavax (NASDAQ:NVAX) rose by 6.9% on Wednesday after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the vaccine sector. See our full article here.

Is now the time to buy Novavax? Access our full analysis report here, it’s free.

Semtech (NASDAQ:SMTC): Semiconductor company Semtech (NASDAQ:SMTC) rose by 9.3% on Monday after the stock continued to rally as the company announced the sale of its cellular module business for $62 million, a move aimed at sharpening its focus on high-growth areas like AI data-center networking. See our full article here.

Is now the time to buy Semtech? Access our full analysis report here, it’s free.

STAAR Surgical (NASDAQ:STAA): Medical lens company STAAR Surgical (NASDAQ:STAA) fell by 8.3% on Monday after sentiment faded following its underwhelming second quarter earnings reported the previous week. See our full article here.

Is now the time to buy STAAR Surgical? Access our full analysis report here, it’s free.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article